Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

15P - Tumour PD-L1 expression and blood biomarkers of activity of adaptive immunity and tumour microenvironment in patients with solid tumours

Date

09 Dec 2020

Session

e-Poster Display Session

Presenters

Anna Malkova

Citation

Annals of Oncology (2020) 31 (suppl_7): S1417-S1424. 10.1016/annonc/annonc389

Authors

A. Malkova, R. Orlova, N. Zhukova, V. Sharoyko, E. Kaledina

Author affiliations

  • Saint-Petersburg state university, Saint-Petersburg/RU
More

Abstract 15P

Background

Tumor PD-L1 overexpression leads to suppression of cytotoxic adaptive immunity. Recently high level of Interleukin-1 beta (IL-1β) in the tumor microenvironment (TME) was reported to be associated with immunosuppression of lymphocytes. The ratio of neutrophils and lymphocytes (NLR) in the tumor tissue and in the peripheral blood reflects the activity of adaptive immunity. The aim of this work is to study the relationship between the tumor expression of the PD-L1, the concentration of serum IL-1β, a possible marker of TME activity, and NLR, a marker of adaptive immunity activity.

Methods

The serum samples of patients with various solid tumors (n=48) before the start of checkpoint inhibitors therapy were collected. The serum level of IL-1-β was measured with ELISA (\"ELISA-best\", Novosibirsk, Russia), tumor PD-L1 expression was determined by immunohistochemical method, a full blood count by cytometry. The results obtained were analyzed in GraphPad Prism 6 (Graph Pad Software, USA) using Fisher, Mann-Whitney, and Spearman's statistical analysis. The project is supported by grant (contract №20-015-00498/20).

Results

Positive PD-L1 expression was observed in 72,92% (35/48) of the patients, while IL-1β was detected in 66,67% (32/48) and high NLR was registered in 35,42% (17/48). The tumor PD-L1 expression had a positive statistically significant low correlation with serum IL-1β concentration (r=0,327; p=0,037) and the NLR (r=0,327; p = 0,034). IL-1β level was positively correlated with NLR (r= 0,353; p= 0,025). In a group with positive PD-L1 expression the mean concentration of IL-1β was 1,65± 0,54 pg/ml, the mean NLR was 4,26±0,94 109/L, what exceeds the meanings of the group with negative expression, but without statistical significance.

Conclusions

The study revealed a positive correlation between the tumor PD-L1 expression, the serum IL-1β concentration and the NLR. The obtained result may indicate the influence of the immunosuppressive properties of the tumor on the state of the patient's immunity. A comprehensive determination of tumor PD-L1 expression, serum IL-1β concentration and NLR can be used as an assessment of the patient's immune status before starting treatment with checkpoint inhibitors.

Legal entity responsible for the study

The authors.

Funding

Russian Foundation for Basic Research (RFBR) - Project number 20-015-0049820 of 19.02.2020.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings